Cabaletta Bio (CABA) Exchange Rate Effect (2024 - 2025)
Cabaletta Bio (CABA) posted quarterly Exchange Rate Effect of -$8000.0 for Q4 2025, up 60.0% year-over-year from -$5000.0 in Q4 2024, and up 27.27% quarter-over-quarter from -$11000.0 in Q3 2025.
Powered by 
Analysis
Cabaletta Bio (CABA) Exchange Rate Effect (2024 - 2025) Analysis & Trends
Cabaletta Bio's Exchange Rate Effect history runs 2 years deep, the most recent figure standing at -$8000.0 for Q4 2025.
- In Q4 2025, Exchange Rate Effect rose 60.0% year-over-year to -$8000.0; the TTM figure through Dec 2025 stood at $19000.0 (up 195.0% YoY), while the FY2025 annual figure was $19000.0, up 195.0% from the prior year.
- Exchange Rate Effect for Q4 2025 stood at -$8000.0, up from -$11000.0 in the prior quarter.
- The five-year high for Exchange Rate Effect was $31000.0 in Q2 2025, with the low at -$20000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -287,000.00 |
| 10 | Cabaletta Bio | 522.26 Mn | 522.26 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -8,000.00 |
| Sep 30, 2025 | -11,000.00 |
| Jun 30, 2025 | 31,000.00 |
| Mar 31, 2025 | 7,000.00 |
| Dec 31, 2024 | -20,000.00 |